| Giant Pharmacy #346 | |
| 5316 New Design Rd, Frederick, Maryland 21703 | |
| (301) 698-9430 |
| Name | Giant Pharmacy #346 |
|---|---|
| Organization Name | Giant Of Maryland Llc |
| Location | 5316 New Design Rd, Frederick, Maryland 21703 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (301) 698-9430 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
UT Southwestern Medical Center scientists have identified a key protein that helps trigger ketamine's rapid antidepressant effects in the brain, a crucial step to developing alternative treatments to the controversial drug being dispensed in a growing number of clinics across the country.
"With donor money to fight HIV and AIDS falling, spending in sub-Saharan Africa must be targeted to get the best results," Bjorn Lomborg, director of the Copenhagen Consensus Center, writes in the Guardian's "Poverty Matters" blog, noting, "Sub-Saharan Africa has 10 percent of the world's population but is home to 70 percent of those living with HIV and AIDS."
Agios Pharmaceuticals, a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced multiple presentations at the American Association for Cancer Research (AACR) 101st Annual Meeting that highlight cancer metabolism as an approach to identify new ways to treat cancer, opening the potential for a new class of cancer drugs targeting metabolic enzymes.
Spontaneous survivors of acetaminophen overdose have significantly lower overall health compared to survivors or transplant recipients following acute liver failure caused by non-drug induced liver injury according to a new study published online in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
Zenobia Therapeutics, Inc. the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.
› Verified 8 days ago
| NPI Number | 1841223195 |
| Organization Name | GIANT OF MARYLAND LLC |
| Doing Business As | GIANT PHARMACY 346 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 5316 New Design Rd, Frederick, MD 21703 |
| Phone Number | 301-698-9430 |
News Archive
UT Southwestern Medical Center scientists have identified a key protein that helps trigger ketamine's rapid antidepressant effects in the brain, a crucial step to developing alternative treatments to the controversial drug being dispensed in a growing number of clinics across the country.
"With donor money to fight HIV and AIDS falling, spending in sub-Saharan Africa must be targeted to get the best results," Bjorn Lomborg, director of the Copenhagen Consensus Center, writes in the Guardian's "Poverty Matters" blog, noting, "Sub-Saharan Africa has 10 percent of the world's population but is home to 70 percent of those living with HIV and AIDS."
Agios Pharmaceuticals, a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced multiple presentations at the American Association for Cancer Research (AACR) 101st Annual Meeting that highlight cancer metabolism as an approach to identify new ways to treat cancer, opening the potential for a new class of cancer drugs targeting metabolic enzymes.
Spontaneous survivors of acetaminophen overdose have significantly lower overall health compared to survivors or transplant recipients following acute liver failure caused by non-drug induced liver injury according to a new study published online in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
Zenobia Therapeutics, Inc. the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.
› Verified 8 days ago
News Archive
UT Southwestern Medical Center scientists have identified a key protein that helps trigger ketamine's rapid antidepressant effects in the brain, a crucial step to developing alternative treatments to the controversial drug being dispensed in a growing number of clinics across the country.
"With donor money to fight HIV and AIDS falling, spending in sub-Saharan Africa must be targeted to get the best results," Bjorn Lomborg, director of the Copenhagen Consensus Center, writes in the Guardian's "Poverty Matters" blog, noting, "Sub-Saharan Africa has 10 percent of the world's population but is home to 70 percent of those living with HIV and AIDS."
Agios Pharmaceuticals, a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced multiple presentations at the American Association for Cancer Research (AACR) 101st Annual Meeting that highlight cancer metabolism as an approach to identify new ways to treat cancer, opening the potential for a new class of cancer drugs targeting metabolic enzymes.
Spontaneous survivors of acetaminophen overdose have significantly lower overall health compared to survivors or transplant recipients following acute liver failure caused by non-drug induced liver injury according to a new study published online in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
Zenobia Therapeutics, Inc. the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.
› Verified 8 days ago
Cvs Pharmacy #01437 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1460b W Patrick St, Frederick, Maryland 21702 Phone: (301) 662-9522 | |
Cvs Pharmacy #02335 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 8032 Liberty Rd, Frederick, Maryland 21701 Phone: (301) 846-0090 | |
Cvs Pharmacy #01484 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 402 S Jefferson St, Frederick, Maryland 21701 Phone: (301) 663-4861 | |
Cvs Pharmacy #02230 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2040 Rosemont Ave, Frederick, Maryland 21702 Phone: (301) 695-4811 | |
Cvs Pharmacy #01518 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 901 W 7th St, Frederick, Maryland 21701 Phone: (301) 694-3390 |